^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | leuprolide acetate for depot suspension (GnRH agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Scottish Medicines Consortium accepts PROSTAP® SR DCS & PROSTAP® 3 DCS (leuprorelin acetate) to treat early and advanced breast cancer
Published date:
02/09/2021
Excerpt:
Takeda is pleased to announce that the Scottish Medicines Consortium has accepted PROSTAP® SR DCS & PROSTAP® 3 DCS (leuprorelin acetate) for use in patients with early breast cancer and advanced breast cancer.
